{"entity":{"id":"mendus","kind":"company","name":"Mendus","aka":[],"tldr":"Mendus makes an off-the-shelf cell-based cancer vaccine, given as a skin injection after standard treatment, to stop leukaemia and ovarian cancer from coming back.","summary":"Mendus AB (Nasdaq Stockholm: IMMU) is headquartered in Stockholm with research and development in Leiden. Lead programme vididencel (DCP-001) is an allogeneic active immunotherapy derived from a proprietary leukaemia cell line; given intradermally it triggers local immune activation and tumour-directed immune responses against residual disease. It is being developed as maintenance therapy in acute myeloid leukaemia (ADVANCE II and CADENCE), in high-risk ovarian cancer (ALISON), where in June 2026 the company reported long-term progression-free survival with broad immune activation and five participants progression-free at long-term follow-up, and in chronic myeloid leukaemia for treatment-free remission (VITAL-CML, first stage fully enrolled in 2026). A second asset, ilixadencel, is an intratumoural allogeneic dendritic cell product. No equity round could be sourced from fetched pages; in June 2026 the company repurchased outstanding warrants from Fenja for about SEK 3.7 million.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.mendus.com"},{"label":"Press releases","url":"https://www.mendus.com/investors/press-releases/"},{"label":"Pipeline and technology","url":"https://www.mendus.com/what-we-do/"}],"tags":[],"related":[],"cancers":["aml","ovarian"],"sections":["immunotherapy"],"technologies":["shared-antigen-vaccine","allogeneic-cell-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year and rights issues not sourced from fetched pages."],"hq":"Stockholm","country":"SE","companyType":"biotech","website":"https://www.mendus.com","ticker":"IMMU.ST","stage":"public","investors":[],"funding":[]},"route":"/companies/mendus/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"allogeneic-cell-therapy","kind":"technology","name":"Allogeneic (off-the-shelf) cell therapy","route":"/technologies/allogeneic-cell-therapy/"},{"id":"shared-antigen-vaccine","kind":"technology","name":"Off-the-shelf cancer vaccines","route":"/technologies/shared-antigen-vaccine/"}]}}